Carisma Therapeutics to Present New Data on Anti-GPC3 In Vivo CAR-M Therapy for Hepatocellular Carcinoma at SITC 2024
CARM 11.05.2024
About Gravity Analytica
Pre-clinical data demonstrate robust anti-tumor activity and a novel off-the-shelf approach for GPC3+ solid tumors
The abstract, titled"Pre-Clinical Efficacy of a Novel Anti-GPC3 In Vivo CAR-M for Hepatocellular Carcinoma,"presents the first pre-clinical data on the development candidate targeting Glypican-3 ("GPC3"), a tumor-associated antigen commonly expressed in HCC. This novel off-the-shelf approach reprograms endogenous myeloid cellsin vivousing lipid nanoparticles ("LNP") to deliver mRNA encoding CARs. The data show that thisin vivoCAR-M therapy has significant potential as a treatment for GPC3+ solid tumors, including HCC.
"Our data at SITC this year highlights the groundbreaking potential of thein vivoCAR-M platform," said
SITC Presentations Details:
Title:Pre-clinical efficacy of a novel anti-GPC3in vivoCAR-M for hepatocellular carcinomaPublication Number:329Session Date & Time:
Title:A Phase 1, First-in-Human study of autologous monocytes engineered to express an anti-HER2 chimeric antigen receptor (CAR) in participants with HER2 overexpressing solid tumorsPublication Number:659Session Date & Time:
The poster presented at SITC 2024 will be available online in the "Publications" section of Carisma's website athttps://carismatx.com/technology/publications/following the start of the poster session.
About Carisma Therapeutics
Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, anticipated discovery, preclinical and clinical development activities for Carisma's product candidates, the potential safety, efficacy, benefits and addressable market for Carisma's product candidates, and clinical trial results for Carisma's product candidates. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. The words "believes," "anticipates," "estimates," "plans," "expects," "intends," "may," "could," "should," "potential," "likely," "projects," "continue," "will," "schedule," and "would" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These forward-looking statements are predictions based on the Company's current expectations and projections about future events and various assumptions. Although Carisma believes that the expectations reflected in such forward-looking statements are reasonable, Carisma cannot guarantee future events, results, actions, levels of activity, performance or achievements, and the timing and results of biotechnology development and potential regulatory approval is inherently uncertain. Forward-looking statements are subject to risks and uncertainties that may cause Carisma's actual activities or results to differ significantly from those expressed in any forward-looking statement, including risks and uncertainties related to Carisma's ability to advance its product candidates, the receipt and timing of potential regulatory designations, approvals and commercialization of product candidates, clinical trial sites and our ability to enroll eligible patients, supply chain and manufacturing facilities, Carisma's ability to maintain and recognize the benefits of certain designations received by product candidates, the timing and results of preclinical and clinical trials, Carisma's ability to fund development activities and achieve development goals, Carisma's ability to protect intellectual property, and other risks and uncertainties described under the heading "Risk Factors" in Carisma's Annual Report on Form 10-K for the year ended
Investors:
Media Contact:
View original content to download multimedia:https://www.prnewswire.com/news-releases/carisma-therapeutics-to-present-new-data-on-anti-gpc3-in-vivo-car-m-therapy-for-hepatocellular-carcinoma-at-sitc-2024-302295745.html
SOURCE